An active murine-human chimeric Fab antibody derived from Escherichia coli, potential therapy against over-expressing VEGFR2 solid tumors

Applied Microbiology and Biotechnology

Volumn 91, Issue 5, 2011, Pages 1341-1351

  Huang, Jianfei ^a,c   Liang, Jie ^c   Tang, Qi ^c   Wang, Zhongchan ^b   Chen, Leru ^b   Zhu, Jin ^b,c   Feng, Zhenqing ^c  

^a NANTONG UNIVERSITY   (China)

^b Huadong Medical Institute of Biotechniques   (China)

^c NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Chimeric Fab; Escherichia coli; Immunological method; VEGFR2

Indexed keywords

CHIMERIC FAB; CLINICAL DEVELOPMENT; FUNCTIONAL PROTEINS; GENE ENGINEERING; HUMAN CANCER; IMMUNOLOGICAL METHODS; MURINE MONOCLONAL ANTIBODY; POTENTIAL THERAPIES; PRE-CLINICAL; SOLID TUMORS; VASCULAR ENDOTHELIAL GROWTH FACTOR; VEGFR-2;

DRUG THERAPY; GENES; MONOCLONAL ANTIBODIES; TUMORS;

ESCHERICHIA COLI;

IMMUNOGLOBULIN F(AB) FRAGMENT; VASCULOTROPIN RECEPTOR 2;

ANTIBODY; COLIFORM BACTERIUM; DRUG; GENE EXPRESSION; IMMUNOASSAY; KINETICS; RECOMBINATION; RODENT; TUMOR;

ANIMAL CELL; ARTICLE; CANCER TISSUE; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ESCHERICHIA COLI; FLUORESCENCE ACTIVATED CELL SORTING; GENE OVEREXPRESSION; GENETIC ENGINEERING; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE TEST; IMMUNOHISTOCHEMISTRY; IMMUNOLOGICAL PROCEDURES; IMMUNOPRECIPITATION; KINETICS; MOUSE; NONHUMAN; PROTEIN EXPRESSION; SOLID TUMOR;

AMINO ACID SEQUENCE; ANIMALS; ANTIBODIES, MONOCLONAL; BASE SEQUENCE; CELL LINE, TUMOR; ESCHERICHIA COLI; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; MICE; MOLECULAR SEQUENCE DATA; NEOPLASMS; RECOMBINANT PROTEINS; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2;

ESCHERICHIA COLI; MURINAE;

EID: 80052632882     PISSN: 01757598     EISSN: 14320614     Source Type: Journal    
DOI: 10.1007/s00253-011-3335-y     Document Type: Article

References (32)

1. F Aires da Silva S Corte-Real J Goncalves 2008 Recombinant antibodies as therapeutic agents: pathways for modeling new biodrugs BioDrugs 22 301 314 10.2165/00063030-200822050-00003 1:CAS:528:DC%2BD1cXht1ejurjI
2. Barbas CF III, Burton DR, Scott JK, Silverman GJ (2001) Phage display: a laboratory manual. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, pp 9.38-9.41
3. NL Bartlett A Younes MH Carabasi A Forero JD Rosenblatt JP Leonard SH Bernstein RG Bociek JM Lorenz BW Hart J Barton 2008 A phase 1 multidose study of SGN-30 immunotherapy in patients with refractory or recurrent CD30+ hematologic malignancies Blood 111 1848 1854 10.1182/blood-2007-07-099317 1:CAS:528:DC%2BD1cXisVeisrg%3D (Pubitemid 351451492)
4. F Bulens AM Vandamme H Bernar L Nelles RH Lijnen D Collen 1991 Construction and characterization of a functional chimeric murine-human antibody directed against human fibrin fragment-D dimer Eur J Biochem 195 235 242 10.1111/j.1432-1033.1991.tb15699.x 1:CAS:528:DyaK3MXhtFOrtr8%3D
5. RT Burtet MA Santos-Silva GA Buss LM Moraes AQ Maranhão MM Brigido 2007 Production of a recombinant Fab in Pichia pastoris from a monocistronic expression vector J Biochem 142 665 669 10.1093/jb/mvm226 1:CAS:528: DC%2BD1cXkvV2jt74%3D (Pubitemid 351197709)
6. N Congy-Jolivet A Probst H Watier G Thibault 2007 Recombinant therapeutic monoclonal antibodies: mechanisms of action in relation to structural and functional duality Crit Rev Oncol Hematol 64 226 233 10.1016/j.critrevonc.2007. 06.013 (Pubitemid 350027814)
7. J Du H Wang C Zhong B Peng M Zhang B Li S Hou Y Guo J Ding 2008 Crystal structure of chimeric antibody C2H7 Fab in complex with a CD20 peptide Mol Immunol 45 2861 2868 10.1016/j.molimm.2008.01.034 1:CAS:528:DC%2BD1cXksFKksbY%3D
8. A Forero-Torres JP Leonard A Younes JD Rosenblatt P Brice NL Bartlett A Bosly L Pinter-Brown D Kennedy EL Sievers AK Gopal 2009 A phase II study of SGN-30 (anti-CD30 mAb) in Hodgkin lymphoma or systemic anaplastic large cell lymphoma Br J Haematol 146 171 179 10.1111/j.1365-2141.2009.07740.x 1:CAS:528:DC%2BD1MXps1OitL8%3D
9. B Groner C Hartmann W Wels 2004 Therapeutic antibodies Curr Mol Med 4 539 547 10.2174/1566524043360483 1:CAS:528:DC%2BD2cXls1aksro%3D (Pubitemid 38961197)
10. JS Heier DS Boyer TA Ciulla PJ Ferrone JM Jumper RC Gentile D Kotlovker CY Chung RY Kim FOCUS Study Group 2006 Ranibizumab combined with verteporfin photodynamic therapy in neovascular age-related macular degeneration: year 1 results of the FOCUS Study Arch Ophthalmol 124 1532 1542 10.1001/archopht.124. 11.1532 1:CAS:528:DC%2BD28Xht12mtbrK (Pubitemid 44748725)
11. J Huang Y Tan Q Tang X Liu X Guan Z Feng J Zhu 2010 A high-affinity human/mouse cross-reactive monoclonal antibody, specific for VEGFR-2 linear and conformational epitopes Cytotechnology 62 61 71 10.1007/s10616-010-9262-4 1:CAS:528:DC%2BC3cXltlyrtbg%3D
12. J Huang X Zhang Q Tang F Zhang Y Li Z Feng J Zhu 2011 Prognostic significance and potential therapeutic target of VEGFR2 in hepatocellular carcinoma J Clin Pathol 64 343 348 10.1136/jcp.2010.085142 1:CAS:528: DC%2BC3MXlvFGqt7c%3D
13. N Jendreyko M Popkov C Rader CF Barbas 3rd 2005 Phenotypic knockout of VEGF-R2 and Tie-2 with an intradiabody reduces tumor growth and angiogenesis in vivo Proc Natl Acad Sci USA 102 8293 8298 10.1073/pnas.0503168102 1:CAS:528:DC%2BD2MXlsV2mtLs%3D (Pubitemid 40800082)
14. W Kim MH Jeong KH Kim IS Sohn YJ Hong HW Park JH Kim YK Ahn JG Cho JC Park DL Cho JC Kang 2006 The clinical results of a platelet glycoprotein IIb/IIIa receptor blocker (abciximab: ReoPro)-coated stent in acute myocardial infarction J Am Coll Cardiol 47 933 938 10.1016/j.jacc.2005.10.054 1:CAS:528:DC%2BD28XitVarur8%3D
15. GA Lazar JR Desjarlais J Jacinto S Karki PW Hammond 2007 A molecular immunology approach to antibody humanization and functional optimization Mol Immunol 44 1986 1998 10.1016/j.molimm.2006.09.029 1:CAS:528:DC%2BD28Xht1Kitb3L (Pubitemid 44827249)
16. N Lonberg 2008 Human monoclonal antibodies from transgenic mice Handb Exp Pharmacol 181 69 97 10.1007/978-3-540-73259-4-4 1:CAS:528:DC%2BD1cXhslSjtLo%3D
17. D Lu X Jimenez H Zhang P Bohlen L Witte Z Zhu 2002 Selection of high affinity human neutralizing antibodies to VEGFR2 from a large antibody phage display library for antiangiogenesis therapy Int J Cancer 97 393 399 10.1002/ijc.1634 1:CAS:528:DC%2BD38XhvVWkuw%3D%3D (Pubitemid 34049034)
18. HQ Miao K Hu X Jimenez E Navarro H Zhang D Lu DL Ludwig P Balderes Z Zhu 2006 Potent neutralization of VEGF biological activities with a fully human antibody Fab fragment directed against VEGF receptor 2 Biochem Biophys Res Commun 345 438 445 10.1016/j.bbrc.2006.04.119 1:CAS:528:DC%2BD28XkslSmsLo%3D
19. J Muzard S Loyau N Ajzenberg P Billiald M Jandrot-Perrus 2006 Antithrombotic recombinant antibodies J Soc Biol 200 365 375 10.1051/jbio:2006040 1:CAS:528:DC%2BD1cXksl2ntA%3D%3D (Pubitemid 47202730)
20. K Nakamura Y Zen Y Sato K Kozaka O Matsui K Harada Y Nakanuma 2007 Vascular endothelial growth factor, its receptor Flk-1, and hypoxia inducible factor-1αare involved in malignant transformation in dysplastic nodules of the liver Hum Pathol 38 1532 1546 10.1016/j.humpath.2007.03.002 1:CAS:528:DC%2BD2sXhtVOgu77L (Pubitemid 47418965)
21. N Nishibori H Horiuchi S Furusawa H Matsuda 2006 Humanization of chicken monoclonal antibody using phage-display system Mol Immunol 43 634 642 10.1016/j.molimm.2005.04.002 1:CAS:528:DC%2BD2MXhtlWhsrjF (Pubitemid 41785391)
22. A Nissim Y Chernajovsky 2008 Historical development of monoclonal antibody therapeutics Handb Exp Pharmacol 181 3 18 10.1007/978-3-540-73259-4-1 1:CAS:528:DC%2BD1cXhslSjtL8%3D
23. AB Norman MK Norman WR Buesing MR Tabet VL Tsibulsky WJ Ball 2009 The effect of a chimeric human/murine anti-cocaine monoclonal antibody on cocaine self-administration in rats J Pharmacol Exp Ther 328 873 881 10.1124/jpet.108.146407 1:CAS:528:DC%2BD1MXislalsLo%3D
24. M Pegram D Ngo 2006 Application and potential limitations of animal models utilized in the development of trastuzumab (Herceptin): a case study Adv Drug Deliv Rev 58 723 734 10.1016/j.addr.2006.05.003 1:CAS:528: DC%2BD28XoslKrsb0%3D (Pubitemid 44247227)
25. M Popkov N Jendreyko G Gonzalez-Sapienza RG Mage C Rader CF Barbas 3rd 2004 Human/mouse cross-reactive anti-VEGF receptor 2 recombinant antibodies selected from an immune b9 allotype rabbit antibody library J Immunol Methods 288 149 164 10.1016/j.jim.2004.03.005 1:CAS:528:DC%2BD2cXks1WksLc%3D (Pubitemid 38739260)
26. ME Rodrigues AR Costa M Henriques J Azeredo R Oliveira 2010 Technological progresses in monoclonal antibody production systems Biotechnol Prog 26 332 351 1:CAS:528:DC%2BC3cXlsVSnsr0%3D
27. M Suzuki M Kato-Nakano S Kawamoto A Furuya Y Abe H Misaka N Kimoto K Nakamura S Ohta H Ando 2009 Therapeutic antitumor efficacy of monoclonal antibody against Claudin-4 for pancreatic and ovarian cancers Cancer Sci 100 1623 1630 10.1111/j.1349-7006.2009.01239.x 1:CAS:528:DC%2BD1MXhtFOhurvF
28. UU Tamhane HS Gurm 2008 The chimeric monoclonal antibody abciximab: a systematic review of its safety in contemporary practice Expert Opin Drug Saf 7 809 819 10.1517/14740330802500353 1:CAS:528:DC%2BD1cXhtlais77P
29. BA Thibodeaux JT Roehrig 2009 Development of a human-murine chimeric immunoglobulin M antibody for use in the serological detection of human flavivirus antibodies Clin Vaccine Immunol 16 679 685 10.1128/CVI.00354-08 1:CAS:528:DC%2BD1MXotV2jur8%3D
30. P Tsirigotis T Economopoulos 2008 Monoclonal antibodies in the treatment of lymphoid malignancies J Steroid Biochem Mol Biol 108 267 271 10.1016/j.jsbmb.2007.09.009 1:CAS:528:DC%2BD1cXhsFyntbc%3D (Pubitemid 351179641)
31. XM Yang JL Xing CG Liao XY Yao Y Li ZN Chen 2008 High efficiency reconstitution of a human-mouse chimeric Fab of CAb-1 antibody specific to human colon cancer Scand J Immunol 68 12 21 10.1111/j.1365-3083.2008.02087.x 1:CAS:528:DC%2BD1cXovFert7Y%3D (Pubitemid 351798397)
32. W Zeng AS Gouw MC van den Heuvel PJ Zwiers PE Zondervan S Poppema N Zhang I Platteel KP de Jong G Molema 2008 The angiogenic makeup of human hepatocellular carcinoma does not favor vascular endothelial growth factor/angiopoietin-driven sprouting neovascularization Hepatology 48 1517 1527 10.1002/hep.22490 1:CAS:528:DC%2BD1cXhsVKmtrfE